<DOC>
	<DOCNO>NCT00000696</DOCNO>
	<brief_summary>To evaluate anti-HIV effect single agent versus combination therapy zidovudine ( AZT ) interferon alfa-2a ( IFN-A2a ) , measure p24 protein expression , viral growth infectivity patient symptomatic HIV disease . To assess safety low dose schedule AZT IFN-A2a , alone combination , measure neutrophil count hepatic transaminase level . To evaluate comparative effect single agent versus combination therapy AZT IFN-A2a CD4 cell count skin test reactivity . AZT known effective treatment HIV infection . However , patient may develop reaction AZT administer long periods time . Combining AZT another drug lower dos might reduce toxicity patient prevent development drug resistant strain . IFN-A2a reduce growth HIV test tube experiment recent study show AZT IFN-A2a use together reduce growth HIV effectively either drug use alone . This study examine effectiveness safety drug give together compare result effectiveness safety drug use alone .</brief_summary>
	<brief_title>A Phase I/II Open Label Study To Evaluate Antiviral Potential Combination Low-Dose Therapy With Zidovudine Interferon-Alpha 2A Patients With Symptomatic HIV Disease</brief_title>
	<detailed_description>AZT known effective treatment HIV infection . However , patient may develop reaction AZT administer long periods time . Combining AZT another drug lower dos might reduce toxicity patient prevent development drug resistant strain . IFN-A2a reduce growth HIV test tube experiment recent study show AZT IFN-A2a use together reduce growth HIV effectively either drug use alone . This study examine effectiveness safety drug give together compare result effectiveness safety drug use alone . AMENDED : 04-18-91 Treatment extend 96 week . Patients see weekly first month month follow initiation combination therapy ( Cohorts 1 , 2 ) , every week treatment week 48 , follow every week duration study . AMENDED : The dos modify one 4 total daily dos AZT one 4 daily dos IFN-A2a . AMENDED : Total treatment period 48 week . AMENDED : 9-24-90 Treatment end 901214 . Original Design : Before begin treatment , patient carefully examine evaluate . Each patient receive medication 24 week , follow 4-week follow-up period . Patients assign randomly one four dosing schedule within one three group stratify accord whether ever receive AZT / IFN-A2a : - Group 1 receive AZT alone 12 week , AZT plus IFN-A2a follow 12 week . - Group 2 receive IFN-A2a alone 12 week , IFN-A2a plus AZT follow 12 week . - Group 3 receive combination AZT IFN-A2a 24 week . Medications administer accord one four possible daily dose schedule AZT plus IFN-A2a ( increase dos ) . AZT take mouth capsule every 6 hour . IFN-A2a give injection skin day . Initially , dose IFN-A2a give one research staff , patient teach give injection . Patients examine weekly first 4 week , every week end study . Patients assign group receive two drug examine weekly 4 week second drug add .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemoprophylaxis Pneumocystis carinii pneumonia ( PCP ) , aerosolized pentamidine . Ibuprofen . Acute therapy ( 7 day ) oral acyclovir . Acute therapy ketoconazole . Patients must : A diagnosis AIDS relate complex well define symptom within 12 month study entry absence concurrent illness condition HIV infection . Estimated life expectancy least 12 week . Positive serum p24 antigen &gt; 70 pg/ml . Patients may receive prior zidovudine ( AZT ) / interferon alpha therapy , provide : The total duration treatment &lt; 6 month . Patients treat &gt; 12 week &lt; 6 month receive continuous therapy ( 14 consecutive day 21 total day treatment period ) . For patient treat = &lt; 12 week , continuous treatment mean &lt; 7 day total treatment period . For patient , washout period = &gt; 4 week must elapse prior study entry . Treatment result major adverse reaction attributable AZT IFNA2a rechallenge randomly assign dosage level would preclude . Exclusion Criteria Coexisting Condition : Patients follow exclude : Acquired immunodeficiency syndrome ( AIDS ) define opportunistic infection . Significant cardiac ( New York Heart Association Class 3 4 ) , hepatic , renal , neurologic disorder . Concurrent neoplasm basal cell carcinoma situ carcinoma cervix . Significant neurological disorder impair patient 's ability give receive inform consent reduce patient 's performance status extent protocol requirement selfadministration drug accurately complete . Concurrent Medication : Excluded : All concomitant medication keep minimum . Chemoprophylaxis Pneumocystis carinii pneumonia ( PCP ) , aerosolized pentamidine . Other antiretroviral agent . Experimental medication . Biologic response modifier . Systemic corticosteroid . Cimetidine . Ranitidine . Aspirin , acetaminophen , nonsteroidal antiinflammatory agent exception ibuprofen . Barbiturates . Cardiac glycoside , antiarrhythmic , vasodilator . Systemic treatment active infection , include pulmonary tuberculosis . Concurrent Treatment : Excluded : Systemic treatment active infection , include pulmonary tuberculosis . Patients follow exclude study : AIDS define opportunistic infection , Kaposi 's sarcoma , AIDS define neoplasms , HIV dementia complex , HIV waste disease . HIV constitutional disease . Any one following : Fever &gt; 38.5 degree persist &gt; 1 month . Involuntary weight loss = &gt; 10 lb 10 percent body weight . Diarrhea define = &gt; 2 liquid stool per day persist least total 14 day without definable cause . Significant cardiac ( New York Heart Association Class 3 4 ) , hepatic , renal , neurologic disorder . Concurrent neoplasm basal cell carcinoma situ carcinoma cervix . Significant neurological disorder impair patient 's ability give receive inform consent reduce patient 's performance status extent protocol requirement selfadministration drug accurately complete . Prior AZT IFNA2a therapy = &gt; 6 month . Previous major adverse reaction AZT IFNA2a . Prior Medication : Excluded : Prior zidovudine ( AZT ) interferon therapy = &gt; 6 month . Excluded within 4 week study entry : Any antiretroviral agent , Cytotoxic chemotherapy , immunomodulator , include corticosteroid . Excluded within 30 day study entry : Antiinfectives agent likely produce hematologic side effect ( e.g. , trimethoprim / sulfamethoxazole ) . Excluded : Cardiac glycoside , antiarrhythmic , vasodilator . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Interferon Alfa-2a</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>